{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:38:12Z","timestamp":1777347492832,"version":"3.51.4"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2000,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Antibiotic-resistant gram-positive bacteria have become an increasing problem in the last two decades. In order to evaluate the prevalence of antibiotic resistance in staphylococcal bloodstream isolates in Germany, 2,042 staphylococci collected in 21 tertiary-care hospitals were investigated during a 3-year period (March 1996 to March 1999). Altogether, 1,448\n            <jats:italic>S. aureus<\/jats:italic>\n            isolates and 594 coagulase-negative staphylococci (CoNS) that comprised 13 different species were included. Furthermore, the antistaphylococcal activities of quinupristin-dalfopristin were compared with those of eight other compounds by the broth microdilution method. The rates of oxacillin resistance in\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            ,\n            <jats:italic>S. epidermidis<\/jats:italic>\n            ,\n            <jats:italic>S. haemolyticus<\/jats:italic>\n            , and other CoNS were 13.5, 69, 90, and 34%, respectively. In oxacillin-resistant strains high rates of resistance (up to 100%) to erythromycin, clindamycin, ciprofloxacin, and gentamicin were also observed. However, no strain appeared to be resistant to vancomycin or quinupristin-dalfopristin. The streptogramin combination exhibited excellent in vitro activity against all staphylococcal species tested, regardless of the patterns of resistance to other drug classes. In terms of MICs at which 90% of the isolates are inhibited, quinupristin-dalfopristin was 2 times more active against\n            <jats:italic>S. aureus<\/jats:italic>\n            isolates, 4 to 16 times more active against\n            <jats:italic>S. haemolyticus<\/jats:italic>\n            , and 8 to 32 times more active against\n            <jats:italic>S. epidermidis<\/jats:italic>\n            than vancomycin or teicoplanin.\n          <\/jats:p>","DOI":"10.1128\/jcm.38.8.2819-2823.2000","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T17:57:36Z","timestamp":1577815056000},"page":"2819-2823","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Nationwide German Multicenter Study on Prevalence of Antibiotic Resistance in Staphylococcal Bloodstream Isolates and Comparative In Vitro Activities of Quinupristin-Dalfopristin"],"prefix":"10.1128","volume":"38","author":[{"given":"Christof","family":"von Eiff","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Institute of Medical Microbiology, Westfa\u0308lische Wilhelms-Universita\u0308t, D-48149 Mu\u0308nster,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf Rene\u0301","family":"Reinert","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Institute for Medical Microbiology, National Reference Center for Streptococci, University Hospital, D-52057 Aachen,2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kresken","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Rho\u0302ne-Poulenc Rorer Arzneimittel GmbH, D-50829 Cologne,3 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Brauers","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Rho\u0302ne-Poulenc Rorer Arzneimittel GmbH, D-50829 Cologne,3 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Hafner","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Institute for Pharmacology, Heinrich-Heine-Universita\u0308t, D-40225 Du\u0308sseldorf,4 Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Peters","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Institute of Medical Microbiology, Westfa\u0308lische Wilhelms-Universita\u0308t, D-48149 Mu\u0308nster,1"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.15"},{"key":"e_1_3_2_4_2","unstructured":"Boyce\nJ. M.\nEpidemiology and prevention of nosocomial infections\nThe staphylococci in human disease.\nCrossley\nK. B.\nArcher\nG. L.\n1997\n309\n330\nChurchill Livingstone\nNew York N.Y"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07324-8"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.135"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00108-4"},{"key":"e_1_3_2_8_2","first-page":"225","article-title":"Pr\u00e4valenz der Antibiotikaresistenz bei klinisch wichtigen Infektionserregern in Mitteleuropa","volume":"5","author":"Kresken M.","year":"1996","unstructured":"Kresken M. Hafner D. Pr\u00e4valenz der Antibiotikaresistenz bei klinisch wichtigen Infektionserregern in Mitteleuropa.Chemother. J.51996225230","journal-title":"Chemother. J."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02561661"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390806"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-2-199901190-00012"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.251"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/520288"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jac\/44.2.263","article-title":"Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin\/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group","volume":"44","author":"Nichols R. L.","year":"1999","unstructured":"Nichols R. L. Graham D. R. Barriere S. L. Rodgers A. Wilson S. E. Zervos M. Dunn D. L. Kreter B. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin\/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.J. Antimicrob. Chemother.441999263273","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_15_2","unstructured":"Normenausschu\u00df-Medizin\nMedizinische Mikrobiologie: Methoden zur Empfindlichkeitspr\u00fcfung von bakteriellen Krankheitserregern (au\u00dfer Mykobakterien) gegen Chemotherapeutika. Teil 4 Bewertungsstufen der minimalen Hemmkonzentration. DIN 58940-4.\n1995\nDeutsches Institut f\u00fcr Normung e.V.\nBerlin Germany"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1762"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79166-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.1999.tb00433.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902183400701"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.2.255"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.4.1020-1027.1998"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000239497"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.1997.tb00277.x"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.38.8.2819-2823.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.38.8.2819-2823.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:45:02Z","timestamp":1646441102000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.38.8.2819-2823.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["10.1128\/JCM.38.8.2819-2823.2000"],"URL":"https:\/\/doi.org\/10.1128\/jcm.38.8.2819-2823.2000","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]},"assertion":[{"value":"2000-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-05-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}